Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer. The company's lead product candidate, LCAR-B38M/JNJ-68284528, is a chimeric antigen receptor (CAR) T-cell therapy that is being developed for the treatment of multiple myeloma, a type of blood cancer. Legend Biotech was founded in 2014 as a subsidiary of GenScript Biotech Corporation and became an independent company in 2019. The company is headquartered in Shanghai, China and has operations in the United States and Europe.
Learn more about Legend Biotech Corporation